Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Targeting the compass complex to overcome resistance in KMT2A-rearranged Acute Myeloid Leukemia

Sandhya Dhiman, Vikramjit Dhillon, Jeff Justin Aguilar, Julie Boerner, Yang Shi, Jay Yang, Suresh Kumar Balasubramanian

Blood (2025) 146 (Supplement 1): 1517.

https://doi.org/10.1182/blood-2025-1517

Published: 2025

Journal Articles

Multiomics-guided ex vivo drug sensitivity testing in Relapsed/Refractory Acute Myeloid Leukemia

Jeff Justin Aguilar, Vikramjit Dhillon, Sikander Chohan, Dakshin Padmanabhan, Sushmitha Nanja Reddy, Asmita Shukla, Nagasai Yalavarthi, Anisha Rajavel, Sonubar Virk, Breanna Williams, Julie Boerner, Yang Shi, Jay Yang, Suresh Kumar Balasubramanian

Blood (2025) 146 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2025-3496

Published: 2025

Journal Articles

Which molecular patterns of high-risk myeloid malignancies are concordantly identified using two machine learning algorithms?

Tariq Kewan, Arda Durmaz, Waled Bahaj, Carmelo Gurnari, Olisaemeka Ogbue, Matteo D'Addona, Ahmad Kiwan, Hussein Awada, Simona Pagliuca, Hetty Carraway, Amer Zeidan, Suresh Kumar Balasubramanian, Taha Bat, Yazan Madanat, Valeria Visconte, Jaroslaw Maciejewski

Blood (2025) 146 (Supplement 1): 3485.

https://doi.org/10.1182/blood-2025-3485

Published: 2025

Journal Articles

Prognostic impact of pre-transplant IPSS-m risk downstaging in Myelodysplastic Syndromes

Asmita Shukla, Jeff Justin Aguilar, Vikramjit Dhillon, Sikander Chohan, Nagasai Yalavarthi, Dakshin Padmanabhan, Sushmitha Nanja Reddy, Anisha Rajavel, Jay Yang, Jaroslaw Maciejewski, Suresh Kumar Balasubramanian

Blood (2025) 146 (Supplement 1): 3872.

https://doi.org/10.1182/blood-2025-3872

Published: 2025

Journal Articles

Enhanced IPSS-m: A comorbidity-integrated model for improved clinical risk stratification in myelodysplastic neoplasms

Vikramjit Dhillon, Jeff Justin Aguilar, Sikander Chohan, Anisha Rajavel, Nagasai Yalavarthi, Dakshin Padmanabhan, Sushmitha Nanja Reddy, Yang Shi, Suresh Kumar Balasubramanian

Blood (2025) 146 (Supplement 1): 3871.

https://doi.org/10.1182/blood-2025-3871

Published: 2025

Journal Articles

Deciphering clonal progression in MDS via longitudinal sequencing

Asmita Shukla, Jeff Justin Aguilar, Vikramjit Dhillon, Sikander Chohan, Nagasai Yalavarthi, Dakshin Padmanabhan, Sushmitha Nanja Reddy, Anisha Rajavel, Suresh Kumar Balasubramanian

Blood (2025) 146 (Supplement 1): 2066.

https://doi.org/10.1182/blood-2025-2066

Published: 2025

Journal Articles

Clinical implications of epigenetic age acceleration as a novel biomarker in Acute Myeloid Leukemia

Vikramjit Dhillon, Jeff Justin Aguilar, Valeria Visconte, Zachary Brady, Julie Boerner, Yang Shi, Suresh Kumar Balasubramanian

Blood (2025) 146 (Supplement 1): 5290.

https://doi.org/10.1182/blood-2025-5290

Published: 2025

Journal Articles

Sequential tracking of FLT3-ITD architecture reveals length-dependant impact on clonal clearance and clinical outcome

Asmita Shukla, Jeff Justin Aguilar, Guru Subramanian Guru Murthy, Yazan Madanat, Clayton Jackson, Julia Anderson, Eno-obong Udoh, Vikramjit Dhillon, Sikander Chohan, Nagasai Yalavarthi, Anisha Rajavel, Holly Webb, David Carr, Jaroslaw Maciejewski, Suresh Kumar Balasubramanian

Blood (2025) 146 (Supplement 1): 5285.

https://doi.org/10.1182/blood-2025-5285

Published: 2025

Journal Articles

Triple-negative myeloproliferative neoplasms (TN-MPN): A meta-analysis of clinical and molecular characteristics

Sushmitha Nanja Reddy, Jeff Justin Aguilar, Dakshin Padmanabhan, Henry Zou, Nagasai Yalavarthi, Asmita Shukla, Sandhya Dhiman, Guru Subramanian Guru Murthy, Clayton Jackson, Yazan Madanat, Julia Anderson, Suresh Kumar Balasubramanian

Blood (2025) 146 (Supplement 1): 5603.

https://doi.org/10.1182/blood-2025-5603

Published: 2025

Journal Articles

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

Blood (2025) 146 (Supplement 1): 239.

https://doi.org/10.1182/blood-2025-239

Published: 2025

Journal Articles

The cachexia hematologic severity score (CHeSS): Use of a laboratory-based tool to predict survival and mutation-associated wasting in Acute Myeloid Leukemia and myelodysplastic syndrome

Sikander Chohan, Nagasai Yalavarthi, Jeff Justin Aguilar, Anisha Rajavel, Asmita Shukla, Sushmitha Nanja Reddy, Dakshin Padmanabhan, Vikramjit Dhillon, Asfar Azmi, Suresh Kumar Balasubramanian

Blood (2025) 146 (Supplement 1): 1735.

https://doi.org/10.1182/blood-2025-1735

Published: 2025

Journal Articles

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Blood (2025) 146 (Supplement 1): 766.

https://doi.org/10.1182/blood-2025-766

Published: 2025

Journal Articles

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Blood (2025) 146 (Supplement 1): 764.

https://doi.org/10.1182/blood-2025-764

Published: 2025

Journal Articles

Domain and Residue Mapping of Autoantibodies to β2GPI Reveals Differences Among Antiphospholipid Syndrome Phenotypes

Suresh Kumar, Deepesh Vaid, Paola Adele Lonati, Arianna Da Via, Marta Tonello, Pier Luigi Luigi Meroni, Vittorio Pengo, Nicola Pozzi

Blood blood.2025029488.

https://doi.org/10.1182/blood.2025029488

Published: 2025

Includes: Supplemental data

Journal Articles

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Blood (2024) 144 (Supplement 1): 3206.

https://doi.org/10.1182/blood-2024-211623

Published: 2024

Journal Articles

Longitudinal Sequencing to Investigate Clonal Evolution in Myeloid Neoplasms

Asmita Shukla, Dakshin Padmanabhan, Paul Kim, Jeff Aguilar, Sushmitha Nanja Reddy, Vikram Dhillon, David Carr, Jay Yang, Julie Boerner, Suresh Kumar Balasubramanian

Blood (2024) 144 (Supplement 1): 4254.

https://doi.org/10.1182/blood-2024-212206

Published: 2024

Journal Articles

Clonal Evolution of TP53 Configurations with Treatment Predict Prognosis in Myeloid Neoplasms

Dakshin Padmanabhan, Jeff Aguilar, Paul Kim, Sandhya Dhiman, Asmita Shukla, Vikram Dhillon, Sushmitha Nanja Reddy, David Carr, Jay Yang, Julie Boerner, Jaroslaw Maciejewski, Suresh Kumar Balasubramanian

Blood (2024) 144 (Supplement 1): 1540.

https://doi.org/10.1182/blood-2024-210037

Published: 2024

Journal Articles

Clinical Significance of HOX and Meis gene Expression Profiling in Acute Myeloid Leukemia

Vikram Dhillon, Jeff Aguilar, Paul Kim, Dakshin Padmanabhan, Sandhya Dhiman, Gregory Dyson, Jaroslaw Maciejewski, Suresh Kumar Balasubramanian

Blood (2024) 144 (Supplement 1): 6162.

https://doi.org/10.1182/blood-2024-212337

Published: 2024

Journal Articles

IPSS-M(r): A Reduced Feature Representation of IPSS-M for Clinical Application

Vikram Dhillon, Jeff Aguilar, Sandhya Dhiman, Dakshin Padmanabhan, Gregory Dyson, Suresh Kumar Balasubramanian, Sushmitha Nanja Reddy

Blood (2024) 144 (Supplement 1): 7499.

https://doi.org/10.1182/blood-2024-212356

Published: 2024

Journal Articles

Clinical and Molecular Insights into the Classification Dilemma: Are MDS/AML Cases Distinct from Secondary AML?

Tariq Kewan, Arda Durmaz, Waled Bahaj, Carmelo Gurnari, Olisaemeka Ogbue, Ahmad Kiwan, Hussein Awada, Hetty E. Carraway, Suresh Kumar Balasubramanian, Taha Bat, Yazan F Madanat, Valeria Visconte, Jaroslaw Maciejewski

Blood (2024) 144 (Supplement 1): 850.

https://doi.org/10.1182/blood-2024-207770

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting the compass complex to overcome resistance in KMT2A-rearranged Acute Myeloid Leukemia

Multiomics-guided ex vivo drug sensitivity testing in Relapsed/Refractory Acute Myeloid Leukemia

Which molecular patterns of high-risk myeloid malignancies are concordantly identified using two machine learning algorithms?

Prognostic impact of pre-transplant IPSS-m risk downstaging in Myelodysplastic Syndromes

Enhanced IPSS-m: A comorbidity-integrated model for improved clinical risk stratification in myelodysplastic neoplasms

Deciphering clonal progression in MDS via longitudinal sequencing

Clinical implications of epigenetic age acceleration as a novel biomarker in Acute Myeloid Leukemia

Sequential tracking of FLT3-ITD architecture reveals length-dependant impact on clonal clearance and clinical outcome

Triple-negative myeloproliferative neoplasms (TN-MPN): A meta-analysis of clinical and molecular characteristics

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

The cachexia hematologic severity score (CHeSS): Use of a laboratory-based tool to predict survival and mutation-associated wasting in Acute Myeloid Leukemia and myelodysplastic syndrome

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Domain and Residue Mapping of Autoantibodies to β2GPI Reveals Differences Among Antiphospholipid Syndrome Phenotypes

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Longitudinal Sequencing to Investigate Clonal Evolution in Myeloid Neoplasms

Clonal Evolution of TP53 Configurations with Treatment Predict Prognosis in Myeloid Neoplasms

Clinical Significance of HOX and Meis gene Expression Profiling in Acute Myeloid Leukemia

IPSS-M(r): A Reduced Feature Representation of IPSS-M for Clinical Application

Clinical and Molecular Insights into the Classification Dilemma: Are MDS/AML Cases Distinct from Secondary AML?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only